SkyCell has secured 62 million Swiss francs in a round of funding. According to a press release at startupticker.ch, the oversubscribed round was led by MVM Partners. Furthermore, existing investors such as the Swiss Entrepreneurs Fund and the venture capital fund of the Banque cantonale de Genève were among the backers.
SkyCell has developed a transport container for temperature-sensitive goods such as medications. Thanks to innovative cooling technology, this weighs less than conventional containers, thus saving CO2. SkyCell’s container is also intelligent: It is fitted with sensors that are linked by software based on blockchain technology. As such, information on the temperature or humidity can be mapped in real time and can be made visible to all parties involved.
The start-up was able to double its sales in the first quarter of 2020 versus the previous year. The press release states that the coronavirus pandemic in particular has shown how important it is to provide rapid, safe transport for important drugs. So, for example, in collaboration with airline KLM, the logistics company UPS, and an American pharmaceutical giant, SkyCell has transported urgently needed pneumococcal vaccines from Japan to Germany and into the Netherlands. According to a press release by SkyCell, these vaccines are highly sensitive to temperature fluctuations.
SkyCell now hopes to use the new capital to grow further. The start-up aims to focus on Asia and the USA above all with this.
SkyCell was founded in 2012 and has its headquarters in Zug.
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com